This week, our featured physician executive is David B. Karpf, M.D.
David B. Karpf has more than 20 years of experience in guiding the clinical development of novel therapeutics, both at growing biotechnology firms and within large pharmaceutical companies. David is responsible for all clinical, regulatory and medical affairs functions related to advancing Virobay’s growing pipeline of novel product candidates.
Before joining Virobay, David served as Chief Medical Officer and Vice President, Clinical Affairs at Metabolex. At Metabolex, he oversaw the development of clinical programs in type 2 diabetes, dyslipidemia, and gout, including 2 INDs, 7 Phase 1 trials and 6 Phase 2 trials.
Prior to Metabolex, David was Executive Director of Clinical Research and Regulatory Affairs at Geron where he provided oversight for Geron’s early clinical programs in cancer and regenerative medicine. Prior to Geron, David was Vice President, Clinical and Regulatory Affairs at Calydon, Inc. Prior to his tenure at Calydon, David was Executive Director of Clinical Research at Roche Global Development in Palo Alto and was responsible for clinical development activities in metabolic bone disease and endocrinology, including managing the Phase 3 pivotal program for Boniva™. David was previously Director of Clinical Research at Merck Research Laboratories in Rahway, New Jersey, where he played a pivotal role in the successful NDA and launch of Fosamax™.
In addition to his industry experience, David has held several academic positions and is currently an adjunct clinical professor of endocrinology with the Stanford University School of Medicine, where he directs one of the endocrine subspecialty clinics. He received his M.D. degree from University of California, San Diego, and served on the faculty at UCSF School of Medicine.